Amy Burroughs Sells 14,583 Shares of Terns Pharmaceuticals (NASDAQ:TERN) Stock

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) CEO Amy Burroughs sold 14,583 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $39.19, for a total transaction of $571,507.77. Following the completion of the sale, the chief executive officer owned 288,976 shares of the company’s stock, valued at $11,324,969.44. The trade was a 4.80% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Terns Pharmaceuticals Price Performance

Shares of NASDAQ TERN traded down $0.23 during midday trading on Wednesday, hitting $39.35. The stock had a trading volume of 1,324,631 shares, compared to its average volume of 2,148,204. The firm has a market cap of $4.08 billion, a P/E ratio of -38.20 and a beta of -0.28. Terns Pharmaceuticals, Inc. has a fifty-two week low of $1.87 and a fifty-two week high of $48.26. The company’s 50-day simple moving average is $38.62 and its 200 day simple moving average is $21.83.

Institutional Investors Weigh In On Terns Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of TERN. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in Terns Pharmaceuticals during the fourth quarter worth approximately $25,000. GAMMA Investing LLC boosted its stake in shares of Terns Pharmaceuticals by 762.4% during the 4th quarter. GAMMA Investing LLC now owns 871 shares of the company’s stock worth $35,000 after acquiring an additional 770 shares during the period. iA Global Asset Management Inc. bought a new position in shares of Terns Pharmaceuticals during the 4th quarter worth approximately $43,000. FNY Investment Advisers LLC acquired a new position in shares of Terns Pharmaceuticals during the 4th quarter worth approximately $80,000. Finally, EverSource Wealth Advisors LLC raised its stake in Terns Pharmaceuticals by 61.6% in the 4th quarter. EverSource Wealth Advisors LLC now owns 2,207 shares of the company’s stock valued at $89,000 after acquiring an additional 841 shares during the period. 98.26% of the stock is owned by institutional investors.

Analysts Set New Price Targets

TERN has been the subject of a number of analyst reports. William Blair upgraded shares of Terns Pharmaceuticals from a “market perform” rating to an “outperform” rating in a report on Monday, November 3rd. HC Wainwright boosted their price target on shares of Terns Pharmaceuticals from $20.00 to $60.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. Citizens Jmp upped their price objective on shares of Terns Pharmaceuticals from $35.00 to $57.00 and gave the company a “market outperform” rating in a research report on Thursday, December 11th. Wall Street Zen upgraded Terns Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday. Finally, Citigroup reissued an “outperform” rating on shares of Terns Pharmaceuticals in a research note on Wednesday, November 26th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $58.11.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.